

**Disclosure of Relevant Financial Relationships with Commercial Companies  
Spring 2023 SWOG Group Meeting**

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the American Medical Association. The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by scientific evidence.

Everyone who is in a position to control the content of continuing medical education activity is required to disclose relevant relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME considers the relationships of the person involved in the CME activity to include the financial relationships of a spouse or partner.

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

All potential conflicts of interest have been resolved before this program.

**A. Financial Disclosures Related to CME Activities and Requirements:**

<b><u>Planner/Faculty Member</u></b>	<b><u>Nature of Relationship</u></b>	<b><u>Company</u></b>
<b>Anjali Advani</b>	Consultant	Amgen, Kite, Glycomimetics, Pfizer, Beam, Jazz, Taiho, Novartis
	Grant/Research Support (Principal Investigator)	Amgen, Pfizer, OBI, BEAM, Incyte, Servier, Immunogen, Kite, Seattle Genetics, Glycomimetics
<b>Manmeet Ahluwalia</b>	Consultant	Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen
	Grant/Research Support (Principal Investigator)	Seagen
	Stock Shareholder (Self-managed)	Mimivax, Cytodyn, MedInnovate Advisors LLC
<b>Syed A. Ahmad</b>	Speaker's Bureau	AbbVie
<b>Sikander Ailawadhi</b>	Consultant	GSK, Sanofi, BMS, Takeda, Beigene, Janssen, Regeneron, Collectar, Pfizer
	Grant/Research Support (Principal Investigator)	GSK, BMS, Pharmacyclics, Amgen, Janssen, Collectar, Abbvie, Ascentage, Sanofi
<b>Nadim Ajami</b>	No Disclosures	
<b>Jennifer Amengual</b>	No Disclosures	
<b>Arya Amini</b>	Consultant	Reflexion
	Speaker's Bureau	AstraZeneca, Takeda Pharmaceuticals
	Grant/Research Support (Principal Investigator)	Varian, Reflexion, Genentech
<b>Banu Arun</b>	Grant/Research Support (Principal Investigator)	Research Grant: CPRIT, NCI, Susan Komen, Department of Defense Research paid to institutions: AbbVie, AstraZeneca
<b>Marie Bakitas</b>	No Disclosures	
<b>Rick Bangs</b>	No Disclosures	

<b>Melissa Beauchemin</b>	No Disclosures	
<b>Justin Bekelman</b>	Consultant	Reimagine Care
<b>Charles Blanke</b>	No Disclosures	
<b>Laura Bukavina</b>	No Disclosures	
<b>Allison Caban-Holt</b>	No Disclosures	
<b>Daniel R. Carrizosa</b>	Consultant Grant/Research Support (Principal Investigator)	Curio Science; Regeneron/Sanofi Astra Zeneca, Merck, GlaxoSmithKline, Takeda, Elevation Oncology
<b>Young Chae</b>	Consultant Speaker's Bureau	Bristol Myers Squibb, XGenentech, Guardant Health, Tempus, Lunit, Biodesix, Roche, Neoimmunetech Jazz Pharmaceutical, Lilly Oncology, BMS, Boehringer Ingelheim, Genentech, AstraZeneca
<b>Mariana Chavez McGregor</b>	Consultant Grant/Research Support (Principal Investigator)	Novartis, Pfizer, Lilly, Roche, Astra Zeneca, Exact Sciences, Zodiac Novartis, Pfizer, Lilly
<b>Saurabh Chhabra</b>	Other: (must specify)	Janssen (Honorarium for Advisory Board)
<b>Elena G. Chiorean</b>	Consultant Grant/Research Support (Principal Investigator)	Pfizer, Ipsen, Cardiff, Stemline, Novartis, Merck, Foundation, G1 Therapeutics, Merus, BMS, IGM Biosciences Boehringer-Ingelheim, Fibrogen, Merck, Cornerstone, AADi, Corcept, Lonza, BioMedValley, Biosplice, Erasca, Novartis, Gilead
<b>Benjamin W. Corn</b>	No Disclosures	
<b>Morgan Cox</b>	No Disclosures	
<b>Megan Daly</b>	Consultant Grant/Research Support (Principal Investigator)	Astra Zeneca, Novocure Genentech, Merck, EMD Serono
<b>Siamak Daneshmand</b>	No Disclosures	
<b>Arvind Dasari</b>	Consultant Grant/Research Support (Principal Investigator)	AAA, Personalis, Illumina, HutchMed Eisai, Xencor, HutchMed, Guardant Health, Naterra
<b>Diwakar Davar</b>	Consultant Speaker's Bureau Grant/Research Support (Principal Investigator)	ACM Bio, Clinical Care Options (CCO), Finch Therapeutics, Gerson Lehrman Group (GLG), Medical Learning Group (MLG), Xilio Therapeut Castle Biosciences Arcus, CellSight Technologies, Immunocore, Merck, Regeneron Pharmaceuticals Inc., Tesaro/GSK

<b>Diwakar Davar (cont.)</b>	Other: (must specify)	US Patent 63/124,231, "Compositions and Methods for Treating Cancer," Dec 11, 2020
<b>Lara Davis</b>	Consultant	Daiichi Sankyo, Springworks
<b>Tiffin Despres</b>	No Disclosures	
<b>Nazli Dizman</b>	No Disclosures	
<b>Tanya Dorff</b>	Consultant	Astellas, Astra Zeneca, Bayer, Janssen, SeaGen
<b>Lee Ellis</b>	Consultant Other: (must specify)	Oncohost LTD, Actuate Therapeutics Inc. Fibrogen (Data Monitoring Committee), New Beta Innovation (Data Monitoring Committee)
<b>Harry Erba</b>	Consultant  Speaker's Bureau  Grant/Research Support (Principal Investigator)  Other: (must specify)	AbbVie, Agios, ALX Oncology, Astellas, Celgene/BMS, Daiichi Sankyo, Genentech, GlycoMinetics, Incyte, Jazz, Kura Oncology, Novartis, Takeda, Trillium  AbbVie, Agios, Celgene/BMS, Incyte, Jazz, Novartis  AbbVie, Agios, ALX Oncology, Amgen, Daiichi Sankyo, Forma, Forty-Seven, Gilead, GlycoMinetics, ImmunoGen, Jazz Macrogenics, Novartis, PTC  Chair IRC: Covance/AbbVie; Chair of AML Registry Steering Cmte: Celgene
<b>Zeynep Eroglu</b>	Consultant  Grant/Research Support (Principal Investigator)	Regeneron, Pfizer, Genentech, Eisai  Pfizer, Boehringer-Ingelheim
<b>Marwan Fakh</b>	Consultant  Grant/Research Support (Principal Investigator)	Genentech, Merck, Essai, Pfizer, Seattle Genetics, Taiho  Agenus, Genentech, Amgen, Verestam
<b>David Feldman</b>	No Disclosures	
<b>Thomas Flaig</b>	Grant/Research Support (Principal Investigator)  Stock Shareholder (Self-managed)  Other: (must specify)	Seattle genetics, Janssen, BMS, Roche/Genentech, Merck, Astrazeneca, Astellas  Aurora Oncology - no relevant drugs being discussed  I have two patents with CU but no clinical agents or agents in testing related to these.
<b>Lauren Fowler</b>	No Disclosures	
<b>Jonathan Friedberg</b>	Other: (must specify)	Patent Royalties (spouse)
<b>Shelley Fuld Nasso</b>	No Disclosures	
<b>Lucy Gansauer</b>	No Disclosures	
<b>Sepideh Gholami</b>	Consultant	Advisory Board for HCC AHPBA, Genentech & QED Therapeutics

<b>Ophira Ginsburg</b>	No Disclosures	
<b>Philip Gold</b>	No Disclosures	
<b>Maggie Goodson</b>	No Disclosures	
<b>Julie R. Gralow</b>	No Disclosures	
<b>Jhanelle Gray</b>	Consultant  Grant/Research Support (Principal Investigator)	AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo, Inc; Eli Lilly and Comp; EMD Serono-Merck KGaA; Janssen Scientific Affairs, LLC; Jazz Pharma; Merck & Co, Inc; Novartis; OncoCyte Biotechnology Comp; Sanofi Pharmaceuticals  Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; G1 Therapeutics; Ludwig Institute of Cancer Research; Merck & Co, Inc; Novartis; Pfizer Inc
<b>Arvind Dasari</b>	Consultant  Grant/Research Support (Principal Investigator)	AAA, Personalis, Illumina, HutchMed  Eisai, Xencor, HutchMed, Gardant Health, Natera
<b>Cara Haymaker</b>	Consultant  Grant/Research Support (Principal Investigator)  Stock Shareholder (Self-managed)	Nanobiotix  Avenge, Iovance, BTG, Sanofi, Dragonfly research support to institution  Briacell
<b>Brandy Heckman-Stoddard</b>	No Disclosures	
<b>Norah Lynn Henry</b>	Consultant  Grant/Research Support (Principal Investigator)	Myovant Pharmaceuticals - highly unlikely to apply to the meeting but wanted it to be complete.  Blue Note Therapeutics (Local PI for pharma-sponsored clinical trial) – highly unlikely to apply to the meeting, but wanted to be complete.
<b>Dawn Hershman</b>	No Disclosures	
<b>Paul Hesketh</b>	No Disclosures	
	Consultant  Grant/Research Support (Principal Investigator)	BMS, Genentech, Merck, SeaGen, AstraZeneca, Karyopharm, ADC Therapeutics, Takeda, Regeneron, Genmab, Pfizer, Caribou, Abbvie, Adicet  BMS, Genentech, Merck, SeaGen, Gilead, AstraZeneca, ADC Therapeutics
<b>Dawn Hershman</b>	No Disclosures	
<b>Brian Hess</b>	Consultant	BMS, ADC Therapeutics
<b>Grace Hillyer</b>	No Disclosures	
<b>Johanna Horn</b>	No Disclosures	
<b>Boyu Hu</b>	Consultant	Novartis, Bristol Meyers Squibb, Eli Lilly, GenMab Celgene

<b>Boyu Hu (Cont'd)</b>	<p>Speaker's Bureau</p> <p>Grant/Research Support (Principal Investigator)</p> <p>Other: (must specify)</p>	<p>MJH Life Sciences, Binaytara Foundation, Patient Power Remedy Health</p> <p>Genentech, Celgene, CRISPR Therapeutics, Morphosys AG, Caribou Biosciences, Repare Therapeutics, Artiva Biotherapeutics</p> <p>Lymphoma Research Foundation (Grant Funding)</p>
<b>Siwen Hu-Lieskovan</b>	No Disclosures	
<b>Syma Iqbal</b>	Consultant	Merck, BMS, Daiichi Sankyo, AstraZeneca
<b>Melinda Irwin</b>	No Disclosures	
<b>Judy Johnson</b>	No Disclosures	
<b>Rebecca Johnson</b>	<p>Consultant</p> <p>Speaker's Bureau</p>	<p>Servier Pharmaceuticals (occasional ad hoc consultant)</p> <p>Servier Pharmaceuticals</p>
<b>Lisa Kachnic</b>	<p>Grant/Research Support (Principal Investigator)</p> <p>Other: (must specify)</p>	<p>Varian, Inc.</p> <p>Royalties/licenses from UpToDate™ as an editor of the bone metastasis chapter; Payment for participation on a Data Safety Monitoring Board for New Beta; Innovation Limited Board member for the RTOG Foundation (no payment)</p>
<b>Karen Kelly</b>	<p>Consultant</p> <p>Grant/Research Support (Principal Investigator)</p>	<p>Amgen, Genentech, AstraZeneca, Sanofi, Takeda</p> <p>Genentech, BMS, Novartis</p>
<b>Hagen Kennecke</b>	No Disclosures	
<b>Mark Klein</b>	No Disclosures	
<b>David Kozono</b>	No Disclosures	
<b>Robert Krouse</b>	No Disclosures	
<b>Mike LeBlanc</b>	No Disclosures	
<b>Seth Lerner</b>	<p>Consultant</p> <p>Grant/Research Support (Principal Investigator)</p> <p>Stock Shareholder (Self-managed)</p> <p>Other: (must specify)</p>	<p>Aura Bioscience, BMS, C2iGenomics, Ferring, Incyte, Pfizer/EMD Serono, Protara, Stimit, UroGen, Vaxiion, Verity</p> <p>Aura Bioscience, Endo, FGD, JBL (SWOG), Genentech (SWOG), Janssen (SWOG), Merck (Alliance), QED Therapeutics, Vaxiion</p> <p>C2i Genomics, Auro Bioscience</p> <p>Patent TGA classifier; honoraria for speaking - Grand Rounds Urology, UroToday</p>
<b>Mark A. Lewis</b>	<p>Consultant</p> <p>Speaker's Bureau</p>	<p>Natera, Pfizer</p> <p>AstraZeneca / Daiichi Sankyo, Astellas</p>

<b>Mark A. Lewis (cont'd)</b>	Other: (must specify)	Medscape (columnist)
<b>Daniel Lin</b>	No Disclosures	
<b>Michael A. Liss</b>	No Disclosures	
<b>Andrew Lowy</b>	Consultant	Kinnate, Fibrogen, Bluestar Genomics, Steba Biotech, Corecpt
<b>Philip Mack</b>	Consultant	Guardant Health
<b>Shakun Malik</b>	No Disclosures	
<b>Joshua Mammen</b>	Consultant Stock Shareholder (Self-managed)	Castle BioSciences, United Healthcare Iovance Biotherapeutics, Doximity
<b>Anne Marie Mercurio</b>	No Disclosures	
<b>Kamara Mertz-Rivera</b>	No Disclosures	
<b>Brian Minton</b>	No Disclosures	
<b>Michelle Mollica</b>	No Disclosures	
<b>Brian Moore</b>	No Disclosures	
<b>Halle Moore</b>	Consultant Grant/Research Support (Principal Investigator)	Moyovant Daiichi_Sankyo, AstraZeneca, Roche/Genentech, Sermonix, Seattle Genetics (all to institution)
<b>Meena Moran</b>	Other: (must specify)	Vice Chair, Breast Panel, National Comprehensive Cancer Network
<b>Samyukta Mullang</b>	No Disclosures	
<b>Jamie Myers</b>	No Disclosures	
<b>Lucia Nappi</b>	Speaker's Bureau Grant/Research Support (Principal Investigator) Other: (must specify)	Pfizer, Astra Zeneca, Bayer Ipsen, Janssen Ipsen, Bayer, Merck
<b>Marian Neuhausser</b>	No Disclosures	
<b>Angelica Nogueira-Rodrigues</b>	Consultant	Roche, AstraZeneca, MSD, Eisai, Pfizer, GSK, Agenus, Daiichi
<b>Kristen O'Dwyer</b>	No Disclosures	
<b>Mark O'Rourke</b>	No Disclosures	
<b>Megan Othus</b>	Consultant Other: (must Specify)	Merck, Biosight DMSC: Celgene, Glycomimetics
<b>Sumanta Pal</b>	Other: (must Specify)	Travel: Ipsen and CRISPR
<b>Ravi B. Parikh</b>	No Disclosures	

<b>Manali I. Patel</b>	No Disclosures	
<b>Sameer Patel</b>	No Disclosures	
<b>Sandip Patel</b>	Consultant  Grant/Research Support (Principal Investigator)	Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina, Merck, Pfizer, Rakuten, Tempus  Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech
<b>Sapna Patel</b>	Consultant  Grant/Research Support (Principal Investigator)  Stock Shareholder (Self-managed)	Advance Knowledge in Healthcare, Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Guidepoint Global, Immatics, Inst clinical trial support cont: Seagen, Syntrix Bio, TriSalus Life Sciences  Institutional clinical trial support: Bristol Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen, Novartis, Provectus  Inst clinical trial support cont: Seagen, Syntrix Bio, TriSalus Life Sciences
<b>Philip Philip</b>	Consultant  Speaker's Bureau  Grant/Research Support (Principal Investigator)  Other: (must Specify)	Daiichi Sankyo, Rafeal Pharmaceuticals, Merck, Trisalus, Merus, Authem, Bayer, Health, Guardant, Servier Seagen, Pfizer  AstraZeneca, Bayer, Incyte, BMS, Servier  Astellas, Bayer, BeiGene, Bristol-Myers Squibb, Corcept Therapeutics, Daiichi Sankyo, Eisai, Gritstone, Incyte, IQVIA Biotech, Merck, Natera, NGM Biopharmaceuticals, Novocure, Pfizer, ED Pharmaceuticals, Syncore, Rafeal, Taiho Oncology, Thyme, Trisalus  DSMB: Erytech Pharma, Advisory Committee: Bayer, Advisory Committee: Daiichi Sankyo, Advisory Committee: Ipsen Biopharmaceuticals, Advisory Committee: Merck, Advisory Committee: Guardant, Advisory Committee: Rafeal Pharmaceuticals, Advisory Committee: Incyte, Advisory Committee: Pfizer, Advisory Committee: Rafeal
<b>Victor Prieto</b>	No Disclosures	
<b>Lajos Pusztai</b>	Consultant  Grant/Research Support (Principal Investigator)	Seagen, Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, GSK, Genentech, Personalis, Natera, Exact Sciences  Susan Komen Foundation, Breast Cancer Research Foundation, NCI, Merck, AstraZeneca, Seagen, Pfizer, Bristol Myers Squibb
<b>Jerald Radich</b>	Consultant	Noavartis, NuProbe, HIG, Cepheid, Amgen, HTG
<b>Scott Ramsey</b>	No Disclosures	
<b>Patrick Reagan</b>	Consultant  Grant/Research Support (Principal Investigator)	Kite Pharma, Caribou Bioscience  Genentech, Seattle Genetics
<b>Karen Reckamp</b>	Consultant	Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Soreno, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati,

<b>Karen Reckamp (Cont'd)</b>	Grant/Research Support (Principal Investigator)	Genentech; Blueprint; Calithera; Daiichi Sankyo; Elevation Oncology; Janssen
<b>Mary Redman</b>	No Disclosures	
<b>Bertrand Routy</b>	Consultant  Grant/Research Support (Principal Investigator)	AstraZeneca, Mercks, Bristol-Myers Squibb, Bayer, Pfizer, Imagia, DaVolterra, Kaleido Biosciences.  AstraZeneca, Mercks, Bristol-Myers Squibb
<b>Mazyar Shadman</b>	Consultant	Eli Lilly
<b>Jonathan G. Sham</b>	No Disclosures	
<b>Priyanka Sharma</b>	Consultant	AstraZeneca, Novartis, Gilead, Merck
<b>Rachna Shroff</b>	No Disclosures	
<b>Brian Shuch</b>	Consultant  Speaker's Bureau  Grant/Research Support (Principal Investigator)	Veracyte, Johnson and Johnson, Merck, Telix, Genentech  Merck  KCA, DOD, Driven to Cure
<b>Harpreet Singh</b>	No Disclosures	
<b>Davendra Sohal</b>	Consultant  Speaker's Bureau  Grant/Research Support (Principal Investigator)	AstraZeneca, Cancer Commons, TransThera, Totus, Valar  Incyte  Ability, Amgen, Apexigen, Astellas, AZ, Bexion, BMS, FibroGen, Genentech, Hengrui, Merck, NextCure, Rafael, Regeneron, Roche
<b>Jonathan Sommers</b>	Consultant	Digital Health Networks, Fred Hutch Cancer Center, Tikkun Patient Advocates
<b>Vernon Sondak</b>	Consultant  Grant/Research Support (Principal Investigator)	Alkermes, BMS, Genesis Drug Discovery & Development, Iovance, Merck, Novartis, OncoSec, Regeneron, Ultimovacs  Neogene Therapeutics, Skyline and Turnstone
<b>Shane Stecklein</b>	No Disclosures	
<b>Patrick Stiff</b>	Consultant  Grant/Research Support (Principal Investigator)	Morphosys  Karyopharm, Amgen, Pfizer, Cellerar, Actinium, Seattle Genetics
<b>Norbert Strauss</b>	No Disclosures	
<b>Jon Strosberg</b>	Consultant  Speaker's Bureau	Novartis  Ipsen Tersera



<b>Jon Strosberg (Cont'd)</b>	Grant/Research Support (Principal Investigator)	Alphamedix, RayzeBio, ITM
<b>Ishwaria M. Subbiah</b>	No Disclosures	
<b>Virginia Sun</b>	No Disclosures	
<b>Paul Swiecicki</b>	No Disclosures	
<b>Ian Thompson</b>	Consultant  Grant/Research Support (Principal Investigator)	Partners/Harvard University, Profound Medical  MagForce
<b>Eric Toloza</b>	Consultant	Genentech, Astra Zeneca, Bristol Myer Squibb, Biodesix, RazorGenomics (formerly Oncocyte)
<b>Meghna S. Trivedi</b>	No Disclosures	
<b>Susanna Ulahannan</b>	Grant/Research Support (Principal Investigator)	AbbVie, Adlai Nortye, ArQule Inc., AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp., Ciclomed LLC, Erasca, Evelo Biosciences Inc., Exelixis, G1 Therapeutics Inc., GlaxoSmithKline GSK, IGM biosciences, Incyte, Isofol, Klus Pharma Inc., Macrogenics, Merck Co. Inc., Mersana Therapeutics, OncoMed Pharmaceuticals Inc., Pfizer, Regeneron Inc., Revolution Medicine Inc., Synemore Biologics Co., Takeda, Tarveda Therapeutics, Tesaro, Tempest, VigeoTherapeutics Inc. <b>all funds to institution</b>
<b>Ulka Vaishampayan</b>	Consultant  Speaker's Bureau  Grant/Research Support (Principal Investigator)	BMS, Bayer, AAA, Gilead, Pfizer, EXelixis, Seattle Genetics, Genzyme, Merck  Genzyme, Bayer, EXelixis  BMS, Merck
<b>Peter Van Veldhuizen</b>	Consultant	Amgen, Astra Zeneca, Daiichi, Bayer, BMS, Merck, Ipsen, Arcus, Astellas, Molecular Templates, Roche, Lilly, Seagen
<b>Zev Wainberg</b>	Consultant	
<b>Courtney Wille</b>	No Disclosures	
<b>Ignacio Wistuba</b>	Consultant  Speaker's Bureau  Grant/Research Support (Principal Investigator)	Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant  Medscape, MSD, Genentech/Roche, Platform Health, Pfizer, AstraZeneca, Merck, Merus  Genentech, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amg
<b>Michael Wu</b>	No Disclosures	
<b>J. Christine Ye</b>	Consultant	Janssen, BMS

<b>J. Christine Ye (Cont'd)</b>	Grant/Research Support (Principal Investigator)	Janssen, Regeneron, BMS, Novartis, Ascentage
<b>James B. Yu</b>	No Disclosures	
<b>David Zhen</b>	Grant/Research Support (Principal Investigator)	Merck, Eli Lilly, Genentech, SeaGen, Legend Biotech, Astra Zeneca, Bristol Myers Squibb

**B. Financial Disclosures Related to Scientific Activities of SWOG**

The relevant policy and process for disclosure of financial conflict of interest within SWOG are governed by Group Policy #35, "Financial Conflict of Interest Policy" (<http://swog.org/Visitors/Download/Policies/Policy35.pdf>) which was established in accordance with (and is consistent with) the Public Health Service regulation entitled "Responsibility of Applicants for promoting Objectivity in Research for which PHS Funding is Sought and Responsible Prospective Contractors" (42 CFR Part 50, 45 CFR 94, final rule published 8/25/2011). Policy #35 is made available to the public via the publicly accessible portion of SWOG's website. Federal regulations require that SWOG management plans be made available within 5 business days upon written request.